Calcium Acetate versus Calcium Carbonate for the Control of Serum Phosphorus in Hemodialysis Patients

1994 ◽  
Vol 14 (3) ◽  
pp. 192-196 ◽  
Author(s):  
Jaume Almirall ◽  
Lluis Veciana ◽  
Joan Llibre
Keyword(s):  
Calcium Carbonate ◽  
Hemodialysis Patients ◽  
Calcium Acetate ◽  
Serum Phosphorus

Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients

1996 ◽  
Vol 10 (5) ◽  
pp. 625-630 ◽  
Author(s):  
Michael Wallot ◽  
Klaus-Eugen Bonzel ◽  
Andreas Winter ◽  
Birgit Geörger ◽  
Bernhard Letten ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Phosphate Binder ◽  
Hemodialysis Patients ◽  
Calcium Acetate

scholarly journals Calcium Acetate or Calcium Carbonate for Hyperphosphatemia of Hemodialysis Patients: A Meta-Analysis

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0121376 ◽  
Author(s):  
Yong Wang ◽  
Guoqiang Xie ◽  
Yuanhang Huang ◽  
Han Zhang ◽  
Bo Yang ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Meta Analysis ◽  
Hemodialysis Patients ◽  
Calcium Acetate

scholarly journals Calcium acetate versus calcium carbonate in the control of hyperphosphatemia in hemodialysis patients

2000 ◽  
Vol 118 (6) ◽  
pp. 179-184 ◽  
Author(s):  
Eufrônio José d'Almeida Filho ◽  
Elisa de Albuquerque Sampaio da Cruz ◽  
Marcos Hoette ◽  
Frederico Ruzany ◽  
Luana Neves Lopes Keen ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Statistical Significance ◽  
Blood Gas Analysis ◽  
Good Alternative ◽  
Hemodialysis Patients ◽  
Gas Analysis ◽  
Calcium Acetate ◽  
Double Blind Study ◽  
Double Blind ◽  
Stage Renal Disease

CONTEXT: Hyperphosphatemia has an important role in the development of bone and mineral abnormalities in end-stage renal disease (ESRD). OBJECTIVE: To compare the phosphorus binding power and the hypercalcemic effect of calcium acetate and calcium carbonate in hemodialysis patients. TYPE OF STUDY: Crossover, randomized, double-blind study. PLACE: A private hospital dialysis center. PARTICIPANTS: Fifty-two patients who were undergoing regular hemodialysis three times a week ([Ca++] dialysate = 3.5 mEq/L). PROCEDURES: Half of the patients were started on 5.6 g/day of calcium acetate and, after a 2 week washout period, received 6.2 g/day of calcium carbonate. The other half followed an inverse protocol. MAIN MEASUREMENTS: Clinical interviews were conducted 3 times a week to monitor for side effects. Determinations of serum urea, calcium, phosphorus, hematocrit, Kt/V and blood gas analysis were obtained before and after each treatment. RESULTS: Twenty-three patients completed the study. A significant increase in calcium plasma levels was only observed after treatment with calcium carbonate [9.34 mg/dl (SD 0.91) vs. 9.91 mg/dl (SD 0.79), P < 0.01]. The drop in phosphorus levels was substantial and significant for both salts [5.64 mg/dl (SD 1.54) vs. 4.60 mg/dl (SD 1.32), P < 0.01 and 5.89 mg/dl (SD 1.71) vs. 4.56 mg/dl (SD 1.57), P < 0.01, for calcium acetate and calcium carbonate respectively]. The percentage reduction in serum phosphorus (at the end of the study) per milliequivalent of salt administered per day tended to be higher with calcium acetate but statistical significance was not found. CONCLUSION: Calcium acetate can be a good alternative to calcium carbonate in the handling of hyperphosphatemia in ESRD patients. When calcium acetate is used, control of hyperphosphatemia can be achieved with a lower administration of calcium, perhaps with a lower risk of hypercalcemia.

Effect of famotidine and lansoprazole on serum phosphorus levels in hemodialysis patients on calcium carbonate therapy

2007 ◽  
Vol 68 (08) ◽  
pp. 93-98 ◽  
Author(s):  
C. Matsunaga ◽  
S. Izumi ◽  
T. Furukubo ◽  
M. Satoh ◽  
T. Yamakawa ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Phosphorus Levels

scholarly journals Effect of Histamine H2-Receptor Antagonist on the Phosphorus-Binding Abilities of Calcium Carbonate and Calcium Lactate in Hemodialysis Patients

1999 ◽  
Vol 10 (5) ◽  
pp. 1090-1094
Author(s):  
NORIHIRO TAKAHASHI ◽  
TETSUO SHOJI ◽  
KEISUKE MATSUBARA ◽  
HIROFUMI HITOMI ◽  
MAYUKO HASHIMOTO ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Hemodialysis Patients ◽  
Calcium Lactate ◽  
Serum Phosphorus ◽  
Phosphorus Level ◽  
Serum Phosphorus Level ◽  
H2 Receptor Antagonist ◽  
Histamine H2 Receptor ◽  
H2 Receptor ◽  
Histamine H2 Receptor Antagonist

Abstract. The effect of histamine H2-receptor antagonist (famotidine) on the phosphorus-binding abilities of calcium carbonate and calcium lactate were examined in 13 chronic hemodialysis patients. In seven patients receiving calcium carbonate, famotidine (20 mg/d) was given because of gastroduodenal disorders, and calcium carbonate was replaced with calcium lactate as a phosphorus binder after 4 wk of treatment with famotidine. With the 4-wk administration of famotidine accompanied by calcium carbonate, the serum phosphorus level increased from 6.3 ± 0.9 to 7.1 ± 0.5 mg/dl (P < 0.05). However, with the substitution of calcium lactate, the serum phosphorus level decreased significantly when compared to that before substitution (6.3 ± 0.2 and 6.0 ± 0.9 mg/dl after 4 and 8 wk of substitution, respectively), despite continued administration of famotidine. Serum calcium, creatinine, alkaline phosphatase, high sensitive parathyroid hormone, blood urea nitrogen, arterial blood pH, and bicarbonate were not significantly altered during the trial period. In six control patients treated with calcium carbonate alone, there were no statistical changes in serum calcium and phosphorus levels after substitution of calcium lactate for calcium carbonate. These results suggest that famotidine significantly affects the phosphorus-binding ability of calcium carbonate, but not that of calcium lactate. A careful observation of changes in the serum phosphorus level should be required in hemodialysis patients receiving calcium carbonate and histamine H2-receptor antagonists. Calcium lactate may be useful as a phosphorus binder in such hemodialysis patients.

Calcium Acetate versus Calcium Carbonate as Phosphate Binders in Hemodialysis Patients

Nephron ◽  
1992 ◽  
Vol 60 (4) ◽  
pp. 423-427 ◽  
Author(s):  
F. Caravaca ◽  
I. Santos ◽  
J.J. Cubero ◽  
J.F. Esparrago ◽  
M. Arrobas ◽  
...  
Keyword(s):  
Calcium Carbonate ◽  
Hemodialysis Patients ◽  
Calcium Acetate ◽  
Phosphate Binders

Calcium Acetate Control of Serum Phosphorus in Hemodialysis Patients

1991 ◽  
Vol 17 (5) ◽  
pp. 544-550 ◽  
Author(s):  
Michael Emmett ◽  
Maryella D. Sirmon ◽  
Wanda G. Kirkpatrick ◽  
Charles R. Nolan ◽  
Gunther W. Schmitt ◽  
...  
Keyword(s):  
Hemodialysis Patients ◽  
Calcium Acetate ◽  
Serum Phosphorus

scholarly journals Implementation and effectiveness of an intensive education program on phosphate control among hemodialysis patients: a non-randomized, single-arm, single-center trial

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Jinmei Yin ◽  
Jun Yin ◽  
Rongli Lian ◽  
Peiqiu Li ◽  
Jing Zheng
Keyword(s):  
Education Program ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Phosphate Binders ◽  
Maintenance Hemodialysis ◽  
Single Center ◽  
Clinical Trial Registry ◽  
Before And After ◽  
Intensive Education ◽  
Phosphate Control

Abstract Background Hyperphosphatemia is a common complication in patients on maintenance hemodialysis. Patients’ adherence to phosphorus control can be improved by consistent education. However, few studies have focused on the model construction and effects of health education on phosphate control for hemodialysis patients. Objective To develop an intensive education program focusing on phosphate control among hemodialysis patients and to analyze the effectiveness of this program. Design A non-randomized, single-arm, single-center trial lasting for 6 months. Setting This program was conducted in a hemodialysis center in a teaching hospital in Zhuhai, China. Participants Patients on maintenance hemodialysis with hyperphosphatemia. Methods An intensive hyperphosphatemia control education program lasting for 6 months was conducted among 366 hemodialysis patients applying the First Principles of Instruction model, which focused on mastering four stages: (a) activation of prior experience, (b) demonstration of skills, (c) application of skills and (d) integration of these skills into real-world activities. The controlled percentage of serum phosphorus, knowledge of hyperphosphatemia, and adherence to phosphate binders before and after the education program were assessed. Results The proportion of controlled serum phosphorus was significantly increased from 43.5 to 54.9% (P<0.001). The scores on the knowledge of phosphate control were improved significantly from 59.0 ± 18.9 to 80.6 ± 12.4 (P < 0.001). The proportion of high adherence to phosphate binders was increased dramatically from 21.9 to 44.5% (P < 0.001). Conclusion The intensive education program can effectively improve serum phosphorus, knowledge of hyperphosphatemia, and adherence to phosphate binders among hemodialysis patients. Trial registration Chinese Clinical Trial Registry, ChiCTR2100042017. Retrospectively registered January 12th, 2021.

Sign in / Sign up

Export Citation Format

Share Document